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The ability to continue combination antiretroviral therapy (cART) in human immunodeﬁciency virus (HIV)
einfected patients undergoing hematopoietic cell transplantation (HCT) for treatment of hematologic ma-
lignancies is likely a critical factor in preventing the establishment of an HIV reservoir in transplanted stem
cells. Thus, we studied the feasibility of continued antiretroviral therapy in our HIV-infected patients un-
dergoing autologous or allogeneic transplantation. All HIV-infected adults undergoing HCT for hematologic
malignancy at Fred Hutchinson Cancer Research Center between 2006 and 2014 were included; most were
enrolled in a prospective clinical study to monitor HIV reservoirs after transplantation (NCT00968630 and
NCT00112593). Non-nucleotide reverse transcriptase inhibitor or integrase-strand inhibitoreanchored anti-
retroviral therapy regimens were continued or selected before HCT by infectious disease physicians. Plasma
HIV RNA was measured every other day for the ﬁrst 2 weeks after transplantation and then every 2 weeks.
Missed doses of cART and reasons for changing the cART regimen during the post-transplantation hospi-
talization were documented through review of inpatient pharmacy records. Seven autologous and 8 alloge-
neic transplantations were performed. In 9 transplantations, the cART regimen was not altered after HCT and
no doses were missed. In 2 patients who required alterations in their cART regimen because of development
of acute renal failure (n ¼ 1) and small bowel obstruction (n ¼ 1) after HCT, enfuvirtide was used as a bridging
component of the regimen. Plasma HIV RNA remained suppressed during the ﬁrst 28 days in 12 of 15
transplantations, and no patients had a plasma HIV RNA >1000 copies/mL during long-term follow up. Non-
nucleotide reverse transcriptase inhibitore and integrase-strand inhibitorebased cART are safe and effective
in HIV-infected persons during the peri-HCT period. Most patients undergoing HCT were able to continue
cART without missed doses. Sustained HIV viremia and emergence of resistance were not detected.
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Hematopoietic cell transplantation (HCT) is the standard
of care for many hematologic malignancies, including leu-
kemias and lymphomas. Post-transplantation survival con-
tinues to improve as patient care protocols mature with timedgments on page 156.
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ty for Blood and Marrow Transplantation.an increasing number of patients, including human immu-
nodeﬁciency virus (HIV)einfected persons [2,3]. In the era of
combination antiretroviral therapy (cART), despite improved
overall survival, HIV-infected persons remain at an 11-fold
increased risk of developing non-Hodgkin lymphoma
(NHL) compared with the general population [4]. In addition,
HIV-infected patients taking cARTmay developmalignancies
that disproportionately affect older individuals, such as
leukemias and myelomas. Although HIV infection has his-
torically been an exclusion criterion for autologous and
Table 1
Pretransplantation Characteristics and Transplantation Information
No. Age/
Sex
Interval from
HIV Diagnosis
to HCT, yr
Malignancy HCT-
CI
Regimen Donor
Myeloablative regimen autologous HCT
1A* 52 M .3 MM 2 Mel 200 Auto
2 32 F 3.4 DLBCL 4 Bu/Mel/T Auto
3 50 M 19.9 DLBCL 2 BEAM Auto
4 60 M .3 DLBCL 2 BEAM Auto
5A* 40 M 15.0 HL 4 CY/VP/TBI-12 Auto
6 28 M 3.0 BL 2 CY/VP/TBI-12 Auto
7 29 M 1.2 BL 1 CY/VP/TBI-12 Auto
Nonmyeloablative regimen allogeneic HCT
8 39 M 9.0 AML 5 Flu/TBI-2 MUD
9 33 M 12.0 AML 4 Flu/TBI-2 MSD
1B* 53 M 1.1 MM 2 Flu/TBI-2 MMUD
10 43 M 6.9 CML CP 5 Flu/TBI-2 MMUD
5B* 43 M 18.3 HL 4 Flu/TBI-2 MUD
11 39 M 3.5 BL 2 Flu/CY/TBI-2 Haplo
Myeloablative regimen allogeneic HCT
12 39 M 1.0 DLBCL 2 CY/TBI-12 MMUD
13 54 M 20.0 AML 4 BU/Clo MUD
M indicates male; MM, multiple myeloma; Mel, melphalan; Auto, autolo-
gous; F, female; DLBCL, diffuse large B cell lymphoma; Bu, busulfan; T,
thiotepa; BEAM, carmustine (BCNH), etoposide, ara-C (cytarabine),
melphalan; HL, Hodgkin lymphoma; Cy, cyclophosphamide; VP, etoposide;
TBI, total body irradiation; BL, Burkitt lymphoma; AML, acute myeloid leu-
kemia; Flu, ﬂudarabine; MUD, matched unrelated donor; MSD, matched
sibling donor; MMUD, mismatched unrelated donor; CML-CP, chronic my-
elogenous leukemia in chronic phase; haplo, haploidentical donor; Clo,
clofarabine.
* Participants 1 and 5 had an autologous transplantation (trans-
plantations 1A and 5A), subsequently had relapsed disease, and then un-
derwent allogeneic transplantation (transplantations 1B and 5B).
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strated that outcomes after autologous transplantation for
NHL are similar in HIV-infected and HIV-uninfected pop-
ulations [2,3]. Outcomes after allogeneic transplantation are
less well known, but several recent reports document
successful nonmyeloablative and myeloablative trans-
plantations in HIV-infected individuals [5-7], reviewed by
Hütter and Zaia [8]. The ﬁrst reported cure of HIV infection in
the “Berlin patient,” Timothy Ray Brown, was achieved
through myeloablative allogeneic C-C motif chemokine re-
ceptor 5 (CCR5) D32/D32 stem cell transplantation for acute
myeloid leukemia [6], which raised interest in understanding
the mechanisms by which cure was achieved in this case.
An important and controversial issue is the management
of cART during the stem cell transplantation procedure. cART
interruptions may occur during the transplantation process
because of concerns about drug interactions between cART
and chemotherapy or immune suppressive drugs, toxicities
such as bone marrow suppression, or inability to take oral
medications because of nausea and mucositis [8-10]. How-
ever, there are drawbacks to withholding cART during HCT,
most notably the potential for reseeding and repletion of the
HIV reservoir [11] and the effects of uncontrolled HIV repli-
cation on engraftment and immune reconstitution. Here, we
report our experience providing transplantation to HIV-
infected patients and demonstrate the feasibility and safety
of providing uninterrupted cART throughout conditioning
and after HCT. We speciﬁcally assessed the cART regimens
used, adherence, toxicities, and virologic outcomes of HIV-
infected persons undergoing HCT.
METHODS
Patients
All HIV-infected adults treated with HCT for a hematologic malignancy
or lymphoma at the Fred Hutchinson Cancer Research Center between 2006
and 2013 were included in this analysis. Nine of the 13 patients were
enrolled in a prospective clinical trial to monitor HIV reservoirs in the post-
transplantation period using myeloablative conditioning (NCT00968630) or
nonmyeloablative conditioning (NCT00112593). To be eligible for HCT, pa-
tients were required to have received cART for at least 1 month before HCT,
with a decrease in viral load by at least 1.5 log copies/mL or with a plasma
HIV RNA level <5000 copies/mL. All patients provided informed consent
and the study was approved by the Fred Hutchinson Cancer Research Center
institutional review board.
Transplantation Procedures
For each patient, the conditioning regimen and the donor source were
selected according to clinical criteria, considering the type of hematologic
malignancy and remission status (Table 1). The HCT comorbidity index
(HCT-CI) was graded using a validated system that accounts for comorbid-
ities that may contribute to nonrelapse mortality, with higher scores asso-
ciated with increased mortality [12,13]. Engraftment was deﬁned as
achievement of a peripheral granulocyte count above 500 cells/mL for 3
consecutive days. Platelet recovery was deﬁned as achievement of a platelet
count >20,000 cells/mL without need for transfusion. The cART regimen
given during HCTwas determined by the consulting infectious disease team.
The intention for all patients was to maintain cART throughout all aspects of
the HCT procedure, including mobilization of peripheral blood stem cells,
conditioning, infusion of cells, and post-transplantation recovery. Changes
in the cART regimenweremade as needed to address inability to tolerate per
oral therapy, drug toxicity, or drug-drug interactions. Patients were given
supportive care, including antibiotic prophylaxis, intravenous immuno-
globulin, intravenous nutrition, and weekly PCR monitoring for reactivation
and pre-emptive treatment of cytomegalovirus (CMV) according to insti-
tutional practices. Supportive care and suppressive or pre-emptive therapies
were not altered because of HIV status or receipt of cART.
Inpatient electronic pharmacy dispensation logs were reviewed for each
patient during the transplantation period and for 30 days after the trans-
plantation (deﬁned as the peri-transplantation period). Baseline and subse-
quent laboratory tests including CD4 counts, plasma HIV RNA levels, and
infectious and transplantation-related complications were abstracted from
the clinical chart.Laboratory Monitoring and Methods
Plasma HIV RNA level
The plasma HIV RNA level wasmeasured at baseline and every other day
during the ﬁrst 2 weeks after transplantation and then every other week for
the participants in the clinical trials. For persons not enrolled in a clinical
trial, plasma HIV RNA levels were measured as clinically indicated. Plasma
HIV RNA was measured with a real-time HIV-1 RT-PCR assay developed at
University of Washington from 2006 to 2009, with a lower limit of detection
of 30 copies/mL, and an Abbott RealTime HIV-1 assay (Abbott Molecular,
Abbott Park, IL) since 2009, with a lower limit of detection of 40 copies/mL.
T cell subsets were measured using an in-house ﬂow cytometry assay.
The Troﬁle RNA or DNA assay (Monogram Biosciences, San Francisco, CA)
was obtained to determine the CCR5/CXCR4 tropism of HIV viral strains in
some patients.
RESULTS
Patient Characteristics
Fifteen HCT procedures were performed on 13 partici-
pants for treatment of hematologic malignancies (Table 1).
Two patients (patients 1 and 5) were given an autologous
HCT (transplantation 1A and 5A) followed by an allogeneic
HCT for treatment of relapsed disease (transplantation 1B
and 5B). The median age at time of transplantation was
42 years (range, 28 to 60), 12 of 13 patients were men, and 9
were Caucasian. The underlying malignancies included NHL
(n ¼ 7), acute myeloid leukemia (n ¼ 3), Hodgkin lymphoma
(n ¼ 1), chronic myeloid leukemia (n ¼ 1), and multiple
myeloma (n ¼ 1). The median HCT-CI was 2 (range, 1 to 5)
[13].
Overall, 7 autologous transplantations and 8 allogeneic
transplantations were performed. Myeloablative condition-
ing regimens were given in 9 cases before autologous (n ¼ 7)
or allogeneic (n ¼ 2) grafts, and nonmyeloablative regimens
were given in 6 cases before allogeneic grafts. All recipients
of allogeneic grafts were given prophylaxis for graft-versus-
host disease (GVHD) with tacrolimus combined with either
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patient given an HLA-haploidentical graft also received post-
transplantation cyclophosphamide. The median time to
neutrophil engraftment after HCT was 16 days (range, 10 to
24 days) and the median time to platelet recovery was
15 days (range, 9 to 34 days).Antiretroviral Therapy
At the time of ﬁrst HCT, patients had been diagnosed with
HIV for a median of 3.5 years (range, .3 to 20.0) and were
classiﬁed by the Centers for Disease Control disease staging
system as HIV stage 2 (n ¼ 1) or 3 (n ¼ 12). Patient 4 was
diagnosed with HIV infection during chemomobilization for
an autologous transplantation and started on cART at that
time. The other patients had been receiving suppressive
cART before transplantation for a median of 3.3 years (range,
.3 to 15 years) and were diagnosed with malignancy while
receiving cART.
Table 2 details the regimen for each patient at the time of
referral for HCT. Most patients were treated with efavirenz
(EFV)- or raltegravir (RAL)-based cART regimens during HCT.
Protease inhibitors were actively avoided because of poten-
tial drug-drug interactions with chemotherapeutic agents
and immunosuppressants [8,14,15]. Eight patients required
no alteration to their cART regimens throughout the trans-
plantation period and 4 others underwent planned drug
substitutions to mitigate hazardous drug interactions: pa-
tient 8 and patient 1B were switched to EFV from nevirapine
and atazanavir/ritonavir, respectively. Two patients under-
going allogeneic transplantations were switched to RAL from
non-nucleotide reverse transcriptase inhibitors (EFV, patient
5B and rilpivirine, patient 13). Patient 10 had breakthrough
viremia with a peak HIV RNA level of 2859 copies/mL
1month before transplantation and had developed anM184I
mutation on RAL/tenofovir (TDF)/emtricitabine (FTC). He
denied lack of adherence to the medication regimen and hadTable 2
Antiretroviral Treatment and HIV Replication during the Pre- and Post-HCT Period
No. ARV Regimen cAR
Pre-HCT At-HCT
Myeloablative regimen autologous HCT
1A ATV/r/TDF/FTC No change .3
2 EFV/TDF/FTC No change* .5
3 RAL/TDF/FTC No change 9.0
4 EFV/TDF/FTC Maraviroc added .3
5A EFV/TDF/FTC Maraviroc added 15.0
6 EFV/TDF/FTC No change .5
7 RAL/TDF/FTC No change 1.2
Nonmyeloablative regimen allogeneic HCT
8 NVP/TDF/3TC/ABC EFV/TDF/FTC/ABC (pill burden, avoid NVP) 9.0
9 EFV/ABC/3TC No change 12.0
1B ATV/r/TDF/FTC EFV/TDF/FTC (avoid PI) 1.1
10 RAL/TDF/3TC EFV/TDF/FTC/ABC/maravirocy
(pretransplantation resistance)
5.0
5B EFV/TDF/FTC RAL/TDF/FTC (avoid NNRTI) 18.3
11 RAL/TDF/FTC No change 3.5
Myeloablative regimen allogeneic HCT
12 RAL/ABC/3TC No change 1.0
13 RPV/TDF/FTC RAL/TDF/FTC
(avoid NNRTI)
3.3
ARV indicates antiretroviral; VL, viral load; ATV, atazanavir; r, ritonavir; NVP, nevi
nucleotide reverse transcriptase inhibitor; RPV, rilpivirine.
If the HIV RNA level was <30 to 40, but still detectable, the level was considered <
* Switched to RAL/TDF/FTC at day 48 to avoid interaction with voriconazole.
y Maraviroc started on day 25; augmented with enfuvirtide days þ98 to 145.no evidence of malabsorption; the reason for the emergence
of resistance was unknown. His regimen was switched to
EFV/TDF/FTC/abacavir/maraviroc and he achieved undetect-
able viral load before transplantation. Two additional pa-
tients with CCR5-tropic HIV had maraviroc (a CCR5
antagonist) empirically added to an EFV-based regimen at
the time of transplantation to provide additional theoretical
protection to the graft from HIV infection.Feasibility of Continuous cART in the Peri-
Transplantation Period
Among the 9 patients given myeloablative conditioning,
mucositis (Common Technology Criteria > grade 1) occurred
in 7 patients, for a median duration of 7 days. Moderate to
severe nausea and vomiting (Common Technology
Criteria > grade 1) occurred in 5 patients. None of the pa-
tients given nonmyeloablative conditioning developed
mucositis or nausea/vomiting. Among the 14 transplantation
for which patients were admitted to the hospital, completely
uninterrupted cART was achieved during and after HCT in 8
(57%), whereas few doses were missed for the remaining 6
procedures. One patient was not admitted to the hospital
during the peri-transplantation period and reported 100%
adherence to antiretroviral therapy. For the 6 patients who
missed doses of cART, reasons included mucositis (n ¼ 2),
nausea (n ¼ 2), small bowel obstruction (n ¼ 1), and acute
kidney injury (n ¼ 1). A median of 3 days of cART were
missed among these patients (range, 1 to 6 days). Patients 7
and 12 each missed 1 day of cART because of mucositis. Pa-
tient 2 missed 6 nonconsecutive days and patient 1A missed
3 consecutive days because of nausea. Patient 6 developed a
partial small bowel obstruction on day þ5 after HCT and
could take nothing by mouth, including his EFV-based cART
regimen for 3 days. Because of the long half-life of EFV
relative to the other drugs in his regimen (TDF/FTC) he was
treated with subcutaneous enfuvirtide on days þ8 to þ12T, yr HIV Stage Baseline CD4 Baseline HIV
RNA, c/mL
Max VL (c/mL), (d)
3 77 (23%) 804 804 (d 0)
3 0 (0%) <30 <30
3 170 (17%) 79 79 (d 0)
3 123 (25%) 42 638 (d 12)
3 255 (29%) 0 <40
3 241 (56%) 0 0
3 247 (22%) <40 60 (mo 9)
3 373 (28%) <30 <30
3 287 (35%) <30 <30
3 493 (17%) <40 <40
3 135 (14%) <40 911y (mo 9)
3 43 (9%) 0 0
3 N/A 0 0
3 37 (5%) 0 <40
2 141 0 <40
rapine; 3TC, lamivudine; ABC, abacavir; PI, protease inhibitors; NNRTI, non-
40. If no plasma HIV was detected, the plasma level was considered to be 0.
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Upon resolution of the small bowel obstruction on day þ13,
the oral regimen EFV/TDF/FTC resumed and enfuvirtide was
discontinued. Patient 5B was intubated on day þ9 for inﬂu-
enza pneumonia. Oral cART was continued during this time
until he developed acute kidney injury on day þ18. At this
time, TDF was discontinued because of concern that TDF was
contributing to renal insufﬁciency. Subsequently, all cART
was held on day þ20 and þ21 and then the regimen was
changed to RAL, renally dosed FTC, and enfuvirtide on
dayþ22. This regimenwas continued through dayþ37when
abacavir was started in place of enfuvirtide. His renal failure
resolved with supportive care and eventually was attributed
to tacrolimus toxicity. Abacavir was eventually stopped
because of skin toxicity and TDF was resumed on day þ51,
without further compromise in renal function. Overall, cART
was administered on 182 (91.5%) of 199 total days of inpa-
tient hospitalization. These data demonstrate the ability to
administer nearly continuous cART therapy throughout
autologous and allogeneic transplantation.Virologic Suppression
During the ﬁrst 28 days after HCT, plasma HIV RNA levels
measured below 40 copies/mL in 12 of 15 transplantations,
including 5 of the 6 patients who missed cART doses
described above. Three cases of detectable HIV RNA in the
peri-transplantation period occurred in patients who were
not virologically suppressed at the time of HCT; none of the
patients had an HIV RNA level >1000 copies/mL (Figure 1).
Patient 4 was diagnosed with HIV 3 months before HCT and
initiated cART with EFV/TDF/FTC, which led to a decline of
the plasma HIV RNA level from 125,500 to 127 copies/mL by
day 0. After HCT, the viral load remained detectable, ranging
from 42 to 638 copies/mL on EFV/TDF/FTC and maraviroc.
Because of concerns about malabsorption of cART, his
regimen was augmented with enfuvirtide on dayþ19.
Subsequently, his plasma HIV RNA level dropped to <40
copies/mL on day þ28 and remained undetectable for the
remainder of the follow-up. Patient 1 A had a baseline
plasma HIV RNA level of 804 copies/mL at the time of
transplantation; follow-up plasma HIV RNA levels were not
available until 8 months after transplantation, when the HIV
RNA level was undetectable. Patient 3 had a baseline plasmaFigure 1. Time course of plasma HIV RNA level in 5 transplantations in patients who h
below the limit of detection throughout follow-up in the remaining 10 transplantatiHIV RNA level of 79 copies/mL, which became undetectable
by day þ25.
Long Term cART and Virologic Suppression
Patients were followed for a median of 259 days after
transplantation (range, 65 days to > 4 years); 12 remained
virologically suppressed throughout this time, no patient
had a plasma HIV RNA level >1000 copies/mL, and none
developed resistance to cART (Figure 1). Two patients had
unsustained low-level virologic replication (“blips”) detec-
ted to <100 copies/mL. Patient 3 experienced a blip to 57
copies/mL on day 76 and 71 copies/mL on day 98, and then
dropped to <40 copies/mL for the remainder of the follow-
up. Patient 7 experienced a single blip to 60 copies/mL at
month 9 and then became undetectable at month 11. No
alterations in cART were made and these were not felt to be
clinically signiﬁcant.
Patient 10 remained virologically suppressed through
month þ5, before posting an HIV RNA level of 52 copies/mL.
His plasma HIV RNA remained detectable through month 9,
when it peaked at 911 copies/mL in the setting of added
immune suppressive therapy for treatment of GVHD, which
developed after donor lymphocyte infusions were given for
treatment of relapsed leukemia. This patient received
augmentation with enfuvirtide for 48 days, and again
became virologically suppressed for the remainder of the
follow-up. These ﬁndings illustrate the successful suppres-
sion of HIV viremia after HCT.
Toxicities and Complications of HCT
The delivery of cART during conditioning and after
transplantation had no apparent effect on the trans-
plantation course. Speciﬁcally, no patient died of complica-
tions related to the conditioning regimen and there were no
apparent adverse interactions with chemotherapy or
immune-suppressing agents. Patient 2 was the only patient
to require an alteration in cART because of drug-drug in-
teractions in the post-transplantation period. She developed
probable pulmonary aspergillosis and switched from EFV/
TDF/FTC to RAL/TDF/FTC to avoid a drug interaction between
EFV and voriconazole. cART was also held for 6 days
(days þ45 to 51) because of persistent vomiting caused by
pseudo-GVHD of the gut. She remained virologically sup-
pressed throughout this period.ad plasma HIV RNA levels above the limit of detection. HIV RNA level remained
ons. T-20, enfuvirtide, DLI, donor lymphocyte infusion.
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plantations. Because renal insufﬁciency and Fanconi’s syn-
drome are TDF-associated toxicities, we assessed patients’
renal function in the peri-transplantation period. We
observed that most patients had a clinically insigniﬁcant
increase in creatinine during the peri-transplantation period,
with median change of .45 mg/dL and median maximum
creatinine of 1.2 mg/dL through day þ30 (Table 3). As
detailed above, patient 5B developed acute renal failure on
day þ18 in the setting of critical illness due to inﬂuenza
pneumonia requiring intubation, vigorous diuresis, and
elevated tacrolimus levels. This patient required dialysis
from day þ23 to þ30, after which time his kidney function
gradually recovered to baseline. TDF was discontinued at
day þ18 and reintroduced on day þ51 with stable renal
function.
Among the 8 allograft recipients, acute GVHD grades II
and III were diagnosed in 6 (75%). In 2 of these patients,
immune suppression had been rapidly tapered for treatment
of relapse, which contributed to the development of GVHD.
All patients with acute GVHD were treated initially with
prednisone dosed at 1 to 2 mg/kg. Pseudo-GVHD was
observed in 2 patients who received autologous HCTs; they
were also treated with prednisone. Patient 12 developed
grade III GVHD of the skin and gut and required antithymo-
cyte globulin.
Infectious complications are detailed in Table 3. CMV
reactivation was detected and treated pre-emptively in 6
patients, 2 of whom had been treated for CMV disease before
transplantation. Adenovirus viremia was treated with cido-
fovir in patient 12. Two patients developed upper respiratory
infections caused by parainﬂuenza or respiratory syncytial
virus, both of which resolved. Patient 5B developed inﬂuenza
A H1N1 pneumonitis diagnosed on dayþ1 after HCT. DespiteTable 3
Complications and Outcomes of HCT
No. Infections Max Cr*
Pre-HCT Post-HCT
Myeloablative regimen autologous HCT
1A None None 1.4
2 None CMV-reactivation
Aspergillus pneumonia
1
3 None CMV-reactivation 1.1
4 None CMV-reactivation 1
5A None Parainﬂuenza URI .9
6 None None 1.2
7 None C. difﬁcile colitis 1.1
Nonmyeloablative regimen allogeneic HCT
8 None CMV-reactivation 1.7
9 None None 1.6
1B CMV enteritis CMV-reactivation
RSV URI
Rhizopus pneumonia
1.3
10 Aspergillus pneumonia CMV-reactivation
Disseminated fusarium
Multiple bacteremias
1.5
5B None Inﬂuenza pneumonitis 6.9
11 None CMV-reactivation 1.7
Myeloablative regimen allogeneic HCT
12 CMV-retinitis CMV-reactivation
Adenovirus viremia
Aspergillus pneumonia
C. difﬁcile colitis
Norovirus enteritis
1.1
13 Fungal pneumonia None .9
Cr indicates creatinine; NA, not applicable, patients went on to receive a second t
virus; IPS, idiopathic pneumonia syndrome.oseltamivir, he developed severe respiratory compromise
and required ventilator support for 22 days, after which he
fully recovered. Fungal infections developed in 4 patients; all
were treated with antifungal therapy that led to a cure in 2
patients (patients 2 and 12). Rhizopus pneumonia contrib-
uted to the death of patient 1B on day þ280 in the setting of
extensive GVHD, which was precipitated by the rapid taper
of immune suppression used to treat leukemic relapse,
and disseminated fusariosis contributed to the death of
patient 10, who also had relapsed disease. Of note, these
infectious complications were typical transplantation-
related infections rather than acquired immunodeﬁciency
syndromeeassociated opportunistic infections.
Mortality
Four (31%) of 13 persons are alive and free of disease; 3 of
these patients had autologous transplantations and 1 had a
nonmyeloablative allogeneic transplantation (Table 3). The
overall median survival of the cohort was .8 years (range, .3
to 7.1 years). Relapsed malignant disease contributed to
death in 8 (62%) of patients. One patient (patient 12) had
grade III GVHD and died from idiopathic pneumonia syn-
drome. No patient died from HIV-related complications.
Discussion
HCT has an expanding role in the treatment of HIV-
infected patients with hematologic malignancies, due in
large parge part to the successful control of HIV viremia with
cART. Here we show the feasibility of continuous cART
therapy during autologous and allogeneic HCT in HIV-
infected patients, with efﬁcient suppression of viremia and
lack of cART-related toxicities and drug-drug interactions.
Ten of 15 patients had no detectable plasma HIV RNA levels
throughout the peritransplantation period. Those who didChange in Cr GVHD Survival, yr Cause of Death
.4 NA NA
.5 6.2
.4 8.7
0 .2 Relapse
.3 NA NA
.22 .5 Relapse
.54 3.4
.6 II/c .8 Relapse
.6 0/0 7.1
.3 II/c .9 Relapse/pneumonia
.9 II/0 1.9 Relapse
5.87 II .3 Relapse
.25 II .3 Relapse
.5 III .4 IPS
0.15 II .75 Relapse
ransplantation; URI, upper respiratory infection; RSV, respiratory syncytial
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not associated with virologic failure [16], and HIV resistance
to cART did not occur.
Interruptions of cART therapy because of gastrointestinal
toxicity (eg, vomiting or severe mucositis) during the peri-
transplantation period were observed in 5 of 10 patients
who received myeloablative conditioning, but these were
short lived, ranging from 1 to 6 days. Notably, we did not
observe viral reactivation during these interruptions.We also
used the injectable antiretroviral agent enfuvirtide to bridge
ART when patients could not take oral medications or when
there was concern for malabsorption. Although our cohort is
small, we did not observe excessive renal toxicity or other
adverse effects that could be ascribed to cART. The rate of
complications, including organ toxicity and GVHD, was
similar to that of contemporary HIV-uninfected patients
treated for similar malignancies with like treatment regi-
mens at our institution [1]. In addition, rates of CMV reac-
tivation and disease were similar to an HIV-negative cohort
[1]. Most infectious complications in this series occurred in
the patients given allografts and were typical of those
observed after allogeneic HCT rather than those associated
with HIV infection, similar to what has been described in
other series of HIV-infected patients undergoing allogeneic
HCT [8]. Although there was a higher mortality rate among
our patients who underwent allogeneic transplantation
compared with that reported among HIV-negative person
who receive transplantations at our institution [1], with the
exception of 1 patient, the cause of death was not because of
complications from the transplantation procedure, as might
be expected in patients with higher HCT-CI scores [13], but
rather was due to disease relapse. This suggests that HCT is
generally well tolerated by HIV-infected patients. A similar
rate of mortality has been shown in other reports of HIV-
infected HCT patients [17].
The uniformly poor outcomes of HIV-infected patients
undergoing HCT in the pre-cART era is the most compelling
reason to use cART throughout the transplantation proce-
dure. Previously, uncontrolled HIV replication directly led to
the deaths of most patients given HCT or donor lymphocyte
infusions, even those suppressed with zidovudine for
9 months before HCT [18-27]. Because HIV replication was
not controlled, donor lymphocytes were rapidly cleared
because of lytic infection from HIV. Most of these early pa-
tients died from progressive malignant disease, regimen-
related toxicities, or poor graft function. In our own early
experience in the pre cART era, myeloablative therapy was
also associated with progressive HIV disease and persistent
HIV replication (measured by viral culture and P24 antigen
detection) during the weeks after transplantation [24].
In contrast, later studies demonstrate that treatment with
cART substantially improves immune function and contrib-
utes to the improved survival of patients with lymphoma
who receive conventional chemotherapy [28-31]. However,
concerns regarding cART-induced alterations in pharmaco-
kinetics of several chemotherapy agents and cART-
medicated blockade of apoptosis of malignant lymphocytes
led some to recommend holding cART during chemotherapy
[9]. Nevertheless, a recent retrospective pooled analysis of
1546 patients treated for NHL found that cART given
concurrently with chemotherapy was associated with a
higher rate of complete remission (odds ratio, 1.89; P¼ .005),
although there was no signiﬁcant difference in overall sur-
vival compared with those not given cART [32]. In a multi-
center study cohort of patients with HIV-associatedlymphoma in the United States, each log10 copy/mL increase
in plasma HIV RNA during the ﬁrst 6 months after lymphoma
diagnosis was associated with a 35% increased risk of mor-
tality [33], supporting the use of cART during chemotherapy.
HCT is a standard treatment for recurrent lymphoma and
other high-risk hematologic cancers and the clinical out-
comes for HIV-infected patients undergoing autologous HCT
have improved substantially in the cARTera, with procedure-
related mortality at <10% [2,34,35]. The European Group for
Blood andMarrow Transplantation analyzed the outcomes of
68 HIV-positive patients given high-dose HCT and reported a
progression-free survival rate of 56% and an overall survival
rate of 61% [3]. Importantly, outcomes of HIV-infected pa-
tients with NHL treated with autologous HCT were similar to
HIV-negative patients. In most instances, cART was withheld
during delivery of chemotherapy and resumed after resolu-
tion of gastrointestinal toxicity. The few reports of allogeneic
HCT in HIV-positive patients vary with respect to the use of
cART during the procedure, but in all cases there was no
obvious toxicity or complication related to antiretroviral
therapy [5,7,10,36].
Theoretically, HCT may also be considered for treatment
of HIV/acquired immunodeﬁciency syndrome by restoring
immune function, including HIV-speciﬁc immune re-
sponses [7]. The single “cure” of an HIV-infected patient was
accomplished by myeloablative allogeneic HCT using HIV-
resistant CCR5 delta32 homozygous donor cells [6]. This
report raised new interest in the potential of HCT as a
component of curative therapy; therefore, the question of
the tolerability of cART during the procedure becomes
important. Unless donor CD4þ T cells are genetically resis-
tant to HIV, they would quickly become infected with the
virus after infusion into a patient not on suppressive ther-
apy. Continuous cART is a logical solution that would
prevent infection of donor cells, improve immune recon-
stitution, and prevent reseeding of the HIV reservoir.
Control of HIV replication with cART throughout
the transplantation period has many potential beneﬁts,
including (1) the prevention of HIV-associated infections (eg,
candida esophagitis and pneumocystis pneumonia) that
would complicate the transplantation procedure, (2) the
prevention of HIV-related organ toxicity (eg, peripheral
neuropathy, nephropathy, and cardiomyopathy) that could
be ampliﬁed by certain chemotherapy agents, (3) improved
bone marrow function leading to enhanced tolerance of
chemotherapy, and (4) the prevention of HIV infection of
donor lymphocytes that could compromise their function
and engraftment.
Concerns regarding drug-drug interactions and over-
lapping toxicities of antiretroviral agents and chemotherapy
agents are now fairly easily managed using newer HIV
medications (Table 4). Preferred regimens at our institution
have evolved over time; although we initially avoided pro-
tease inhibitors and preferred EFV-containing regimens, we
now consider integrase strand inhibitors, such as RAL or
dolutegravir, to be preferred agents because of their lack of
drug-drug interactions with transplantation medications. In
particular, patients who require voriconazole for treatment
of aspergillus pneumonia will not be able to obtain a thera-
peutic serum level while on EFV or other non-nucleotide
reverse transcriptase inhibitors because of induction of
the P450 cytochrome system. The use of integrase-strand
inhibitore anchored cART has been recommended in HIV-
infected patients undergoing chemotherapy [37] and has
been shown to be well tolerated and effective both in
Table 4
Antiretroviral Agents: Common Toxicities and Drug Interactions
ARV Agent Common Toxicity Metabolism Transplantation-Related
Drug Interactions
Recommendation
Nucleoside reverse transcriptase inhibitors
ABC Hypersensitivity reaction,
rash, fever, malaise
Alcohol dehydrogenase Minimal Preferred if donor and
recipient are HLAB5701
negative
FTC Hyperpigmentation Renal excretion Minimal Preferred
3TC Few Renal excretion Minimal Preferred
TDF Proximal tubulopathy Renal excretion Minimal Preferred if no potential
of renal toxic regimen
Integrase-strand inhibitors
Dolutegravir Rash, insomnia, headache Glucuronidation Minimal Preferred
RAL Rash, nausea, headache Glucuronidation Minimal Preferred
Elvitegravir/cobsicitat
(available as: Stribild)
Nausea, diarrhea, increase
in SCr
CYP450 [Cyclosporine, tacrolimus,
voriconazole
Avoid
Non-nucleoside reverse transcriptase inhibitors
EFV Vivid dreams, rash CYP450 inducer YCyclosporine tacrolimus,
voriconazole
Alternative
Rilpivirine Rash CYP450 inducer May prolong QTc, monitor Alternative
Protease inhibitors
ATV (given with and without
ritonavir)
Hyperbilirubinemia jaundice CYP450 inhibitor [Cyclosporine, tacrolimus,
voriconazole
Avoid
Darunavir (given with ritonavir) Rash, hepatoxicity, diarrhea CYP450 inhibitor [Cyclosporine, tacrolimus,
voriconazole
Avoid
Lopinavir/ritonavir (Available
as Kaletra)
Diarrhea CYP450 inhibitor [Cyclosporine, tacrolimus,
voriconazole
Avoid
Entry inhibitors
Enfuvirtide Injection site reactions Catabolism to its
constituents
Minimal Preferred if unable to
take PO
Maraviroc Hepatotoxicity, rash CYP450 Voriconazole Consider for CCR5
tropic virus
Pharmacokinetic enhancers
Ritonavir Diarrhea CYP450 inhibitor [Cyclosporine, tacrolimus,
voriconazole
Avoid
Cobicistat Increase SCr without
reducing GFR
CYP450 inhibitor [Cyclosporin, tacrolimus,
voriconazole
Avoid
CYP indicates cytochrome P; SCr, serum creatinine; PO, per oral; GFR, glomerular ﬁltration rate.
Included agents are listed as “preferred or alternative” regimens in Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.
http://aidsinfo.nih.gov/guidelines. Accessed February 4, 2015.
Note: Avoid use of drugs that are no longer “preferred” or “alternative” in the DHHS guidelines, including stavudine, didianosine), zidovudine, nevirapine, and
multiple protease inhibitors. [ ¼ Increased levels, Y ¼ Decresed levels.
Table 6
Recommendations for Use of cART in HIV-Infected Persons Undergoing HCT
C. Johnston et al. / Biol Blood Marrow Transplant 22 (2016) 149e156 155patients undergoing chemotherapy and HCT [38]. Oral
solutions and parenteral formulations of many antiretroviral
agents are available for patients having difﬁculty taking
oral treatments (Table 5). Combination tablets with
preferred agents may also improve adherence in the peri-
transplantation setting, particularly in those patients with
signiﬁcant gastrointestinal toxicity. Finally, the use of the
CCR5-blocking agent, maraviroc, for patients whose HIV
strains exclusively use CCR5 may theoretically offer addi-
tional protection for donor cells from subsequent HIVTable 5
Preferred and Alternative Antiretroviral Agents: Formulation and Route of
Administration
Agent Formulation and Route of Administration
ABC 300 mg tablet, 20 mg/mL oral solution
FTC 200 mg hard gelatin capsule; 10 mg/mL oral solution
3TC 150 mg, 300 mg tablets; 10 mg/mL oral solution
TDF 300 mg tablets; oral powder
EFV 600 mg capsules, tablets
Dolutegravir 50 mg tablets
RAL 400 mg tablets, chewable tablets, oral suspension
Enfuvirtide 90 mg subcutaneous injectable
Maraviroc 150 mg and 300 mg tablets
Reference: Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected
Adults and Adolescents. http://aidsinfo.nih.gov/guidelines. Accessed
February 4, 2015.infection. The use of maraviroc in patients receiving alloge-
neic HCT may recapitulate the Berlin patient’s experience [6]
by providing a functionally CCR5-minus state, making HIV
cure a possibility, although this hypothesis requires further
study.
Our ﬁndings are limited by the small size of our cohort
and the observational nature of the data. HIV-infectedUse fully suppressive cART throughout the transplantation procedure
When possible, switch patients to integrase inhibitoreanchored (RAL or
dolutegravir) antiretroviral regimens (instead of NNRTI or PI-
anchored regimens) for the transplantation period to avoid drug-
drug interactions.
Avoid using antiretroviral drugs that inhibit the metabolism of
medications used throughout transplant thereby leading to enhanced
toxicity; namely protease inhibitors such as ATV, darunavir, ritonavir,
and cobicistat
Avoid using toxic antiretroviral agents, such as stavudine, didanosine,
zidovudine, that are no longer listed as preferred or alternative
agents in the DHHS Adult ART Treatment Guidelines
Avoid cART interruptions and use parenteral agents such as enfuvirtide
to bridge periods when patients cannot take oral medications
Consult with an HIV specialist when making antiretroviral changes to
ensure the effectiveness and tolerability of the cART regimen
NNRI indicates non-nucleoside reverse transcriptase inhibitors; DHHS,
Department of Health and Human Services.
C. Johnston et al. / Biol Blood Marrow Transplant 22 (2016) 149e156156persons requiring HCT are a relatively rare and difﬁcult to
study population because of the heterogeneity of underlying
malignancies and the type of transplantation and condi-
tioning regimen used.
Although large, multicenter collaborations are needed to
study the optimization of cART dosing strategies and regi-
mens for control of HIV infection during HCT, these studies
are difﬁcult to complete. Therefore, based on our experience
as well as others [37,38], we have outlined recommendations
for principles of use of cART in HIV-infected individuals
undergoing HCT (Table 6). Our experience suggests that
cART is safe and effective for control of HIV replication in
HIV-infected persons undergoing HCT. The availability of
antiretrovirals that have low pill burden, few toxicities, and
lack of drug-drug interactions allow cART to be continued
without compromising the transplantation procedure.
Therefore, we strongly advocate use of cART for HIV-infected
individuals requiring HCT for treatment of hematologic
malignancies.
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